

Alzheimer's Disease vs. Type 3 Diabetes: Role of Impaired Insulin Actions in the Brain



de la Monte Laboratory
Rhode Island Hospital
Brown Medical School
Providence, RI

Early Abnormalities in AD

- ◆ Metabolic:
 - ◆ Reduced oxygen and glucose metabolism in the cerebral cortex
- ◆ Structural:
 - ◆ Dystrophic neurites and neurofibrillary tangles, phospho-tau, ubiquitin
 - ◆ Amyloid- β deposits
- ◆ Functional:
 - ◆ Acetylcholine deficiency and loss of cholinergic neurons

Fundamental Problems Behind the Scene

- ◆ Metabolic

- ◆ Not known. Few studies showed improved cognition with insulin administration or cognitive impairment in Type 1 diabetes

- ◆ Structural

- ◆ Gene mutations, oxidative stress including mitochondrial dysfunction, ischemia, unknown

- ◆ Functional

- ◆ Loss of cholinergic neurons (why?)

Why Focus on Insulin Actions in the Brain?

- ◆ Studies linked neuronal thread protein (NTP) over-expression in AD to neuronal insulin resistance
- ◆ Ethanol-induced neurodegeneration caused by insulin resistance
- ◆ Chemical knock-out of insulin producing cells in the brain causes AD-type dementia





Questions Raised

- ◆ Is Alzheimer's disease associated with abnormalities in insulin-mediated function in the brain?
- ◆ Are abnormalities in insulin-mediated functions detectable early in the course of AD, and do the abnormalities worsen with progression of neurodegeneration?


Study Design

- ◆ Postmortem banked human brain tissue
 - ◆ Different stages of AD or normal aging
 - ◆ Brown Brain Bank
 - ◆ Massachusetts General Hospital ADRC
 - ◆ Duke University
- ◆ RNA (PCR) and Protein (Western blots immunohistochemical staining, binding assays)
- ◆ Quantitative analysis of data

Decreased Growth Factor Receptor Expression in AD



Decreased Growth Factor Gene Expression in AD




Loss of Cholinergic Neurons in AD Linked to Death of Insulin & IGF-1 Receptor⁺ Neurons

IN-R

IGF1-R

ChAT


ChAT







IN-R + ChAT

IGF1-R + ChAT

Increased Oxidative Stress in AD- Second Arm of Neurodegeneration




Animal Model of Type 3 Diabetes/AD




AD-Type Neurodegeneration in Experimental Type 3 Diabetes Model

Control

ic-STZ




APP-A β




AD-Type Molecular Abnormalities in ic-STZ Model


IN/IGF-II








IN-R/IGF-II-R



IN/IGF-II Binding



APP/ChAT



C STZ

C STZ

C STZ



C STZ

Increased DNA Damage/Oxidative Stress in ic-STZ Model



8-OHdG

4-HNE

Control




ic-STZ





Impaired Learning/Memory in Experimental Type 3 Diabetes

Morris Water Maze


■ Control
▨ ic-STZ



Effects of Insulin & IGF Receptor Depletion on Neuronal Viability and Mitochondrial Function



Hypothetical Scheme: Mechanisms of Neurodegeneration in AD



Future Directions

- ◆ Utilize in vivo model to:
 - ◆ Screen for novel therapeutic compounds to restore insulin/IGF responsiveness
 - ◆ Develop methods to detect insulin/IGF-II depletion and resistance in the CNS
- ◆ Identify genes that mediate insulin resistance and insulin gene depletion in the CNS

Credits

- ◆ Eric Steen
- ◆ Enrique Rivera
- ◆ Nataniel Lester-Coll
- ◆ Ming Tong
- ◆ Alison Goldin
- ◆ Noah Fulmer
- ◆ Stephanie Soscia
- ◆ Ariel Cohen
- ◆ Jack R. Wands
- ◆ NIAAA, NCI (NIA-funded brain banks)